title: Chemoprevention with aromatase inhibitors--trial strategies.
abstract: Estrogen and its catechol metabolites from both the circulation and synthesized within the breast are important in the pathogenesis of breast cancer. Blocking estrogen's effects on the breast with selective estrogen receptor modulators (SERMS) is an ongoing strategy. Thus, tamoxifen and raloxifene reduce risk as monotherapy. Aromatase (estrogen synthetase) inhibitors are a logical alternative to SERMS. To date, SERMS have demonstrated reduction only in estrogen-progesterone receptor positive cancers without reduction in receptor negative tumors. By inhibiting the parent estrogens and their catechol metabolites, true prevention of cancer initiation might occur and reduction not only in the receptor positive but also negative tumors might result. Ongoing adjuvant breast cancer trials are exploring aromatase inhibitors as alternatives to tamoxifen, or in sequence or in combination with tamoxifen. Relative efficacies including reduction in contralateral breast cancer, toxicities and end-organ effects and impact on quality of life, are being explored. Data from these trials will help to guide future chemoprevention strategies. Proof of principal trials in 'high risk' cohorts such as premalignant breast lesions, dense screening mammograms, high plasma estradiol levels or increased bone density are already ongoing. Issues such as dose, schedule, therapeutic index and mono versus combination therapy are important to define.
authors.affiliation: Princess Margaret Hospital, University Health Network, 610 University Avenue, Room 5-303, Ontario, M5G 2M9, Toronto, Canada. pegoss@interlog.com
authors.forename: P E
authors.initials: PE
authors.lastname: Goss
authors.forename: K
authors.initials: K
authors.lastname: Strasser
mesh_terms: D000818:Animals; D047072:Aromatase Inhibitors; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000517:prevention & control*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000633:toxicity; D020847:Estrogen Receptor Modulators / Q000494:pharmacology; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control; D009376:Neoplasms, Hormone-Dependent / Q000517:prevention & control*; D010865:Pilot Projects; D051381:Rats; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology; D013629:Tamoxifen / Q000494:pharmacology
chemical_list: D047072:Aromatase Inhibitors; D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; D020847:Estrogen Receptor Modulators; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen